Market Cap 14.87B P/E 26.43 EPS this Y -4.60% Ern Qtrly Grth 329.50%
Income 667.11M Forward P/E 10.07 EPS next Y 21.80% 50D Avg Chg -8.00%
Sales 5.2B PEG 1.02 EPS past 5Y 2.78% 200D Avg Chg -12.00%
Dividend 2.00% Price/Book 4.02 EPS next 5Y 11.50% 52W High Chg -26.00%
Recommedations 2.00 Quick Ratio 0.54 Shares Outstanding 687.56M 52W Low Chg 3.00%
Insider Own - ROA 3.98% Shares Float 1.10B Beta 0.10
Inst Own 43.98% ROE 10.73% Shares Shorted/Prior 4.03M/3.90M Price 15.21
Gross Margin 44.83% Profit Margin 12.83% Avg. Volume 649,692 Target Price 28.62
Oper. Margin 19.46% Earnings Date - Volume 634,892 Change -0.26%
Grifols, S.A. News
07/28/21 Alkahest Strengthens Management Team with Addition of César Cerezo as Chief Medical Officer
07/14/21 GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564
07/14/21 Moving Average Crossover Alert: Grifols (GRFS)
06/02/21 Grifols to provide Korean Red Cross with Procleix Panther for blood screening, extending donor testing leadership in Asia
06/01/21 Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B
05/25/21 GigaGen Publishes Research Describing Potential New Avenues to Overcome Resistance to anti-PD-L1 Therapies
05/19/21 Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona
04/28/21 Grifols and Andorran government will establish world-class immunology research hub to expand global knowledge of the immune system and develop therapeutics
04/15/21 GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology
04/15/21 Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030
04/09/21 Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021
04/02/21 Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19
03/25/21 Grifols Procleix UltrioPlex E and Procleix Babesia assays receive CE mark
03/23/21 GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
03/22/21 Grifols installs first-ever DG Reader Net analyzer in North America
03/18/21 Grifols launches patient point-of-care system for monitoring infliximab in Europe
03/09/21 Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins
03/08/21 Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s Disease
03/08/21 New Strong Sell Stocks for March 8th

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

GRFS Chatroom

User Image LeviTrade Posted - 9 hours ago

$GRFS Waiting for Buy signal on GRFS with https://www.ultraalgo.com/?afmc=UltraShorterKing

User Image C_H Posted - 16 hours ago

$ADMA Take a look at $GRFS max chart and see what happens to a plasma company when they start turning a profit and hitting full stride. When this rips, it’ll rip for at least a year

User Image MontanaJ Posted - 18 hours ago

$GRFS Work for the company opening 21 centers for Grifols. We never miss a deadline. Impeccable track record with FDA!

User Image LeviTrade Posted - 07/31/21

$GRFS Waiting for Buy signal on GRFS with https://www.ultraalgo.com/?afmc=UltraShorterKing

User Image cctranscripts Posted - 07/30/21

Report of foreign issuer [Rules 13a-16 and 15d-16] https://www.conferencecalltranscripts.com/summary/?id=9710932 $GRFS

User Image risenhoover Posted - 07/30/21

$GRFS / Grifols files form 6-K https://fintel.io/sf/us/grfs?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

User Image Newsfilter Posted - 07/30/21

$GRFS Form 6-K (report of foreign issuer [rules 13a-16 and 15d-16]) filed with the SEC https://newsfilter.io/a/2500a8e76ec4c0caeb45526a1f9d069a

User Image briefingcom Posted - 07/30/21

$GRFS and ImmunoTek Bio Centers enter into collaboration to develop 21 new plasma collection centers https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=IN20210730062622GRFS

User Image cctranscripts Posted - 07/30/21

Report of foreign issuer [Rules 13a-16 and 15d-16] https://www.conferencecalltranscripts.com/summary/?id=9709626 $GRFS

User Image Newsfilter Posted - 07/30/21

$GRFS Form 6-K (report of foreign issuer [rules 13a-16 and 15d-16]) filed with the SEC https://newsfilter.io/a/d18564d66a3d5331bb262eef25ac3cc4

User Image risenhoover Posted - 07/30/21

$GRFS / Grifols files form 6-K https://fintel.io/sf/us/grfs?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

User Image Quantisnow Posted - 07/29/21

$GRFS 📜 SEC Form 6-K filed by Grifols, S.A. https://quantisnow.com/insight/1546561?s=s 30s delayed.

User Image risenhoover Posted - 07/29/21

$GRFS / Grifols files form 6-K https://fintel.io/sf/us/grfs?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

User Image cctranscripts Posted - 07/29/21

Grifols just filed its Report of foreign issuer [Rules 13a-16 a http://www.conferencecalltranscripts.org/include?location=http://www.sec.gov/Archives/edgar/data/1438569/000110465921097375/0001104659-21-097375-index.htm $GRFS

User Image Newsfilter Posted - 07/29/21

$GRFS Form 6-K (report of foreign issuer [rules 13a-16 and 15d-16]) filed with the SEC https://newsfilter.io/a/cc1a300cd01a728fb324cf0e582afeb8

User Image tickeron Posted - 07/29/21

$GRFS reports Earnings today. Wow this is a big change! $GRFS's 10-day Moving Average broke below its 50-day Moving Average on July 1, 2021. View odds for this and other indicators: https://srnk.us/go/2914515

User Image T8SK1 Posted - 07/29/21

$GRFS Tweet Trends Today's Change 34 % + https://t8sk.com/GRFS

User Image tickeron Posted - 07/29/21

Does this make you nervous? $GRFS's 10-day Moving Average crossed below its 50-day Moving Average on July 1, 2021. View odds for this and other indicators: https://srnk.us/go/2914131

User Image tickeron Posted - 07/28/21

Grifols SA - ADR - Level III to report earnings on July 29, 2021. Earnings per share (EPS) estimate: $0.26 $GRFS https://srnk.us/go/2912505

User Image fla Posted - 07/28/21

$GRFS [15s. delayed]: Issued Press Release on July 28, 08:00:00: Alkahest Strengthens Management Team with Addition of César Cerezo as Chi https://s.flashalert.me/85twFd

User Image Quantisnow Posted - 07/28/21

$GRFS 📰 Alkahest Strengthens Management Team with Addition of César Cerezo as Chief Medical Officer https://quantisnow.com/insight/1526871?s=s

User Image Newsfilter Posted - 07/28/21

$GRFS Alkahest Strengthens Management Team with Addition of César Cerezo as Chief Medical Officer https://newsfilter.io/a/698458564c50977892a2cdf0fdead115

User Image T8SK1 Posted - 07/24/21

$GRFS Tweet Trends Today's Change 34 % + https://t8sk.com/GRFS

User Image Hacko Posted - 07/22/21

$GRFS Money to be made here too. For the record.

User Image Tralker Posted - 07/22/21

$GRFS 4 new watchers joined this board today. Yikes https://tralker.com/symbol/GRFS

User Image Stonkmoon Posted - 07/20/21

ɢʟᴛᴀ. $GRFS ** Re-post 13 hours ago ** 2021-07-20 06:00 ET Grifols further expands its activity in Africa with agreement to set up an intravenous solutions manufacturing plant in Nigeria https://stonkmoon.com/news/GRFS/ceae2272a2ffc371f9882630cd4d5262

User Image T8SK1 Posted - 07/20/21

$GRFS Tweet Trends Today's Change 34 % + https://t8sk.com/GRFS

User Image Stonkmoon Posted - 07/20/21

$GRFS 2021-07-20 06:00 ET Grifols further expands its activity in Africa with agreement to set up an intravenous solutions manufacturing plant in Nigeria https://stonkmoon.com/news/GRFS/ceae2272a2ffc371f9882630cd4d5262

User Image Stonkmoon Posted - 07/19/21

ɢʟᴛᴀ. $GRFS ** Re-post 12 hours ago ** 2021-07-19 06:00 ET Grifols further expands its activity in Africa with agreement to set up an intravenous solutions manufacturing plant in Nigeria https://stonkmoon.com/news/GRFS/31772cc4da6be4eac61c696b24342433

User Image WizardsSleeve Posted - 07/19/21

$GRFS

Analyst Ratings
Credit Suisse Outperform Mar 23, 21
HSBC Buy Mar 11, 21
Santander Buy Oct 28, 19
JP Morgan Overweight Jun 27, 19
Berenberg Hold Feb 8, 19
Morgan Stanley Underweight Oct 1, 18
Morgan Stanley Underweight Mar 1, 18
Nomura Buy Mar 17, 16
Berenberg Buy Feb 9, 16